Loading company…
Sequana Medical develops devices and therapies for fluid overload related to liver disease, heart failure, and cancer.
Founded in 2006 and based in Ghent, Belgium, Sequana Medical develops treatments for fluid overload associated with liver disease, heart failure, and cancer. Its products include the implanted alfa pump® system and Direct Sodium Removal (DSR®) therapy. The company raised EUR 27.5 million through an IPO in February 2019, selling shares at EUR 8.5 each. Its CEO is Ian Crosbie, alongside Noel Johnson.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in